New therapy update--A unique combination formulation in the treatment of inflammatory acne

Cutis. 2003 Jul;72(1 Suppl):16-9.

Abstract

Duac Topical Gel (clindamycin 1%-benzoyl peroxide 5%) is a uniform, aqueous gel manufactured under the US Food and Drug Administration (FDA) Current Good Manufacturing Practice (cGMP) regulations and controls, which ensure that consistent product is delivered to the patient every time. Since the product is premixed, the patient does not have to wait for mixing or compounding by the pharmacist. The active ingredients have been shown to be stable for 60 days at room temperature, so that neither the patient nor the physician needs to store the product in the refrigerator. When kept at temperatures of 2 degrees C to 8 degrees C, the product is stable for 2 years. In a clinical study of 358 subjects with moderate to moderately severe acne vulgaris, once-daily treatment with clindamycin 1%-benzoyl peroxide 5% for 11 weeks reduced inflammatory lesions by 53% and noninflammatory lesions by 25%. Good or excellent global response was experienced in 50% of subjects. Overall tolerance ratings were good to excellent in 99% of subjects, and, except for mild to moderate expected local reactions, there were no adverse events related to treatment.

Publication types

  • Clinical Trial
  • Comparative Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acne Vulgaris / drug therapy*
  • Acne Vulgaris / pathology*
  • Administration, Topical
  • Adolescent
  • Adult
  • Benzoyl Peroxide / therapeutic use*
  • Clindamycin / therapeutic use*
  • Dose-Response Relationship, Drug
  • Double-Blind Method
  • Drug Administration Schedule
  • Drug Combinations
  • Female
  • Follow-Up Studies
  • Gels
  • Humans
  • Male
  • Patient Satisfaction
  • Probability
  • Reference Values
  • Risk Assessment
  • Severity of Illness Index
  • Treatment Outcome

Substances

  • Drug Combinations
  • Gels
  • Clindamycin
  • Benzoyl Peroxide